DIRAmed LLC is developing a technology platform for continuous, non-invasive detection of clinically significant analytes in the human body. As its first focus, DIRAmed is developing a working prototype of a glucose-monitoring system to establish proof-of-concept (POC). POC will enable DIRAmed to license the non-invasive glucose technology to one or more strategic partners with commercial interests in the global glucose monitoring markets. DIRAmed is also planning the development of a Hospital Critical Care Product (HCCP) for use in the intensive care setting of acute care hospitals to simplify glucose monitoring for the purpose of Tight Glycemic Control (TGC).